Diosmin and hidrosmin

Observational studies

In 170 out-patients chronic venous insufficiency was significantly improved by Daflon 1 g/day for 1 year, with beneficial effects on functional discomfort, supramalleolar circumference, and calf circumference; the main adverse reaction was gastralgia in seven patients [ ].

In 20 women with primary or secondary lymphedema who took hidrosmin 400 mg tds limb volume was significantly reduced and edema, pain, loss of function, and trophic changes improved [ ].

In an open study in 10 women aged 44–64 years Daflon 500 mg for 6 months reduced the volume of lymphedema in the arms by 6.8% and improved symptoms [ ].

In a prospective non-randomized study in 14 patients with isolated strangulated hemorrhoids, who were treated with a single large dose of injection sclerotherapy plus oral Daflon, the symptoms had resolved completely in 13 at 12 weeks; no adverse reactions were reported [ ].

In an open study of Daflon in 50 pregnant women with acute hemorrhoids, 66% had relief from acute symptoms by the 4th day; there were no reported effects on the course of the pregnancy, fetal development, birth weight, infant growth, or feeding [ ].

Standard compression therapy for leg ulcers in chronic venous insufficiency has been compared with compression therapy plus Daflon in 150 patients. The addition of Daflon was associated with significantly more healed ulcers and significant improvement in the sensation of heavy legs; no treatment-related adverse reactions were reported [ ].

In a randomized study in 63 patients with third-degree hemorrhoids there was no significant difference between no treatment and Detralex in symptoms after ambulatory stapled hemorrhoidopexy [ ].

Comparative studies

In a controlled double-blind comparison of hidrosmin and diosmin in 20 patients with chronic venous insufficiency, hidrosmin was more efficacious; there were no important adverse reactions [ ].

In a randomized comparison of ispaghula husk alone, rubber band ligation plus ispaghula husk, and Daflon plus ispaghula husk in 162 patients with bleeding hemorrhoids the short-term benefits were greatest in the last group but there were no significant differences in recurrence rates at 6 months; no adverse reactions were reported [ ].

In a randomized comparison of Daflon and Venoruton, which contains oxerutins, in 90 patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis, after 8 weeks there was symptomatic improvement only with Venoruton; no adverse reactions were reported and there were no drop-outs [ ].